The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and β-catenin, in prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 5, 2010, Pages 534-540

  Contreras, Hector R ^a   Ledezma, Rodrigo A ^a   Vergara, Jorge ^a,c   Cifuentes, Federico ^a   Barra, Cristina ^a   Cabello, Pablo ^a   Gallegos, Ivan ^b   Morales, Bernardo ^c   Huidobro, Christian ^b   Castellón, Enrique A ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^c HOSPITAL DIPRECA   (Chile)

Author keywords

Epithelial mesenchymal transition; Prostate cancer; Syndecans

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; SYNDECAN 1; SYNDECAN 2; UVOMORULIN;

ARTICLE; BASOLATERAL MEMBRANE; CANCER GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIAL MESENCHYMAL TRANSITION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE STUDY;

BETA CATENIN; BIOLOGICAL MARKERS; CADHERINS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; SYNDECAN-1; SYNDECAN-2;

EID: 77956293543     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.03.018     Document Type: Article

References (27)

1. Bernfield M., Götte M., Woo P., et al. Functions of cell surface heparan sulfate proteoglycans. Ann Rev Biochem 1999, 68:729-777.
2. Park P., Pier G., Preston M., et al. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa. J Biol Chem 2000, 275:3057-3064.
3. Rapraeger A. Molecular interactions of syndecans during development. Semin Cell Dev Biol 2001, 12:107-116.
4. Granés F., Garcia R., Casaroli-Marano R., et al. Syndecan-2 induces filopodia by active cdc42Hs. Exp Cell Res 1999, 248:439-456.
5. Granes F., Rocamora N., Ureña J., et al. Ezrin links syndecan-2 to the cytoskeleton. J Cell Science 2000, 113:1267-1276.
6. Cohen A., Woods D., Marfatia S., et al. Human CASK/LIN-2 binds syndecan-2 and protein 4.1 and localizes to the basolateral membrane of epithelial cells. J Cell Biol 1998, 142:129-138.
7. Ethell I., Yamaguchi Y. Cell surface heparan sulfate proteoglycan syndecan-2 induces the maturation of dendritic spines in rat hippocampal neurons. J Cell Biol 1999, 144:575-586.
8. Beauvais D., Rapraeger A. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2004, 7:2-3.
9. Stanley M., Liebersbach B., Liu, et al. Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells. J Biol Chem 1995, 270:5077-5083.
10. Wiksten J., Lundin J., Nordling, et al. A prognostic value of syndecan-1 in gastric cancer. Anticancer Res 2000, 20:4905-4907.
11. Anttonen A., Kajanti M., Heikkila P., et al. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 1999, 79:558-564.
12. Rintala M., Inki P., Klemi P., et al. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Gynecol Oncol 1999, 75:372-378.
13. Mennerich D., Vogel A., Klaman I., et al. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer 2004, 40:373-382.
14. Contreras H.R., Fabre M., Granés F., et al. Syndecan-2 expression in colorectal cancer-derived HT-29 M6 epithelial cells induces a migratory phenotype. Biochem Biophys Res Commun 2001, 28:742-751.
15. Han I., Park H., Oh E. New insights into syndecan-2 expression and tumorigenic activity in colon carcinoma cells. J Mol Histology 2004, 35:319-326.
16. Fears C., Gladson C., Woods A. Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem 2006, 281:14533-14536.
17. Orozco A., Fromigué O., Bazille C., et al. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Res 2007, 67:3708-3715.
18. Chen D., Adenekan B., Chen L., et al. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 2004, 63:402-407.
19. Kiviniemi J., Kallajoki M., Kujala I., et al. Altered expression of syndecan-1 in prostate cancer. APMIS 2004, 112:89-97.
20. Ruifrok A.C., Johnston D.A. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001, 23:291-299.
21. Zellweger T., Ninck Ch, Bloch M., et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005, 113:619-628.
22. Essner J., Chen E., Ekker S. Syndecan-2. Int J Biochem and Cell Biol 2006, 38:152-156.
23. Gleason D., Mellinger G. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58-64.
24. Munesue S., Yoshitomi Y., Kusano Y., et al. A novel functions of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 2007, 282:28164-28174.
25. Peinado H., Olmeda D., Cano A. Snail, Zeb, and bHLH factors in tumor progression: An alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428.
26. Jaggi M., Johansson S., Baker J., et al. Aberrant expression of E-cadherin and β-catenin in human prostate cancer. Urol Oncol 2005, 23:402-406.
27. Foty R., Steinberg M. Cadherin-mediated cell-cell adhesion and tissue segregation in relation to malignancy. Int J Dev Biol 2004, 48. 397-409.